Clinical trials: Lymphatic System Neoplasm
Procedural Sedation and Analgesia, Pediatric ALL
Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring
This is a prospective, monocentric diagnostic study aiming to evaluate whether a sedation score obtained by a per-procedural electroencephalogram (EEG), the PSI score, could identify patients for whom a 2 μg/kg dose of DEX would…
- Trial name
- DINAMO (NCT06867289)
- Testing
- EEG
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myeloproliferative Disorders, Leukemia
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00305682
- Testing
- anti-thymocyte globulin, cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Mantle Cell Lymphoma
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis.
- Conditions
- Leukemia, Mantle Cell Lymphoma, Myelofibrosis
- Trial name
- NCT00081874
- Testing
- RAD001
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
The objectives of the study are to assess the safety and tolerability of a single dose of SHP674 in Japanese participants (dose confirmation) in the tolerability assessment period of Part 1 and to assess the safety…
- Trial name
- NCT04067518
- Testing
- SHP674
- Where
- 8 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Institut de Recherches Internationales Servier
Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
This study will examine the effects of an experimental drug called UCN-01 (7-hydroxystaurosporine) on T-cell lymphomas. UCN-01 inhibits the growth of several different tumor cells, and, in laboratory studies, it has worked…
- Trial name
- NCT00082017
- Testing
- UCN-01 (7-hydroxystaurosporine)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Autoimmune Lymphoproliferative Syndrome, Lymphoma
Fluorodeoxyglucose Imaging Studies to Detect Lymphoma
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of the lymph system. People with ALPS often have swollen lymph nodes, especially in the neck and armpit.
- Trial name
- NCT01672918
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
B-Cell Acute Lymphoblastic Leukemia (B-ALL)
CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
To learn more about the long-term health in patients treated for B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Cluster of Differentiation antigen 19 (CD19) -redirected chimeric antigen receptor (CAR) T-cells.
- Trial name
- NCT07048535
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia
Phase l/II Study of Ruxolitinib for Acute Leukemia
The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease.
- Trial name
- NCT01251965
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukaemia
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
The main purpose of this study is : 1. To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or…
- Trial name
- Myechild01 (NCT02724163)
- Testing
- Gemtuzumab ozogamicin, Liposomal daunorubicin, Mitoxantrone
- Where
- 68 sites in Australia, France and 4 more
- Volunteers
- 700 people
- Sponsor
- University of Birmingham
Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY 1. Will the new risk group stratification (especially of T-ALL) to improve overall and event-free survival? 2.
- Trial name
- ALL-MB 2015 (NCT03390387)
- Testing
- Dexamethasone continuous, Dexamethasone intermittent, Dexamethasone
- Where
- 58 sites in Armenia, Belarus and 3 more
- Volunteers
- 4,000 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hodgkin Lymphoma
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs)…
- Trial name
- NCT03407144
- Testing
- pembrolizumab, doxorubicin, vinblastine
- Where
- 93 sites in United States, Brazil and 14 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
To understand the incidence of ADRs of Calquence 100 mg capsules (acalabrutinib) used in patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) in a real-world post-marketing…
- Trial name
- NCT04872621
- Where
- 59 sites in Japan
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
This study investigates cancer care delivery in adolescent and young adult patients with acute lymphoblastic leukemia. Surveying institutions, evaluating delivery of care at the patient level and seeking input from healthcare…
- Trial name
- NCT03204916
- Testing
- Discussion, Medical Chart Review, Questionnaire Administration
- Where
- 482 sites in United States, Puerto Rico
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Hodgkins Lymphoma, Non-hodgkins Lymphoma
Brown Fat Activity and White Fat Accumulation
White and brown adipocytes differ in their expression of hormones, cytokines, and inflammatory factors, and they modulate different biological functions.
- Trial name
- NCT01517581
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Children's Hospital Los Angeles
Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.
- Conditions
- Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT06151730
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Haematological Malignancy, Malignancy
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called…
- Conditions
- Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders
- Trial name
- DETERMINE (NCT05770544)
- Testing
- Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Leukemia
STI571 in Treating Patients With Recurrent Leukemia
RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00004932
- Testing
- imatinib mesylate
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
The purpose of this study is to estimate the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) regimen and characterize the pharmacokinetics (PK) of brigatinib monotherapy (film-coated tablets and age-appropriate…
- Conditions
- Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors
- Trial name
- NCT04260009
- Testing
- Brigatinib, Brigatinib AAF
- Sponsor
- Takeda
Hypertension, Osteonecrosis
Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
This is a randomized unblinded Phase II clinical trial evaluating the impact of intensive antihypertensive control (targeted to the 50-75th percentile for age, sex, and height) compared to conventional antihypertensive control…
- Conditions
- Hypertension, Osteonecrosis, Osteonecrosis Due to Drug
- Trial name
- NCT04401267
- Testing
- Intensive Antihypertensive Therapy, Conventional Antihypertensive Therapy, Symptom Survey
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- St. Jude Children's Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.